Accès gratuit
Numéro
Thérapie
Volume 61, Numéro 6, Novembre-Décembre 2006
Page(s) 481 - 489
Section Évaluation du médicament/Drug Evaluation
DOI https://doi.org/10.2515/therapie:2007002
Publié en ligne 15 février 2007
  1. Courcier-Duplantier S, Bouhours P, Pinton P, et al. Groupe de travail Attractivite de la France du Leem. A survey on the position of France in international clinical research as assessed by pharmaceutical laboratories. Therapie 2004; 59(6): 629-38
  2. Mant D. Can randomised trials inform clinical decision about individual patients? Lancet 1999; 353(9154): 743-6
  3. Sculpher MJ, Pang FS, Drummond MF, et al. Generalisability in economic evaluation studies in health care: a review and case studies. Health Technology Assessment (Winchester, England). 8(49):iii-iv, 1-192, 2004 Dec.
  4. Bjornsson TD, Wagner JA, Donahue SR, et al. Review and assessment of potential sources of ethnic differences in drug responsiveness. The Journal of Clinical Pharmacology 2003; 43: 943-67
  5. Martinez MN, McGilveray I. AAPS/RAPS/CAPRA collaborative program: exploring the challenges of drug regulation in a global environment: clinical concerns. Aaps Pharmsci. 2003; 5(4): E27
  6. Morimoto T, Fukui T, Lee TH, et al. Application of US guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med 2004; 117: 459-68
  7. Sakai F, Iwata M, Tashiro K, et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study. Cephalalgia 2002; 22(5): 376-83
  8. Shunsuke Ono, Osamu Kato, Kiichiro Tsutani, et al. Utilisation of foreign clinical data in Japanese new drug approval review: on what basis did the regulatory agency accept them? International Journal of Pharmaceutical Medicine 2004; 18(3): 159-65
  9. Liu JP, Chow SC. Bridging studies in clinical development. J Biopharm Stat 2002; 12(3): 359-67
  10. Yusuf S, Reddy S, Ounpuu S, et al. Global Burden of cardiovascular diseases Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001; 104(23): 2855-64
  11. West of Scotland Coronary prevention Study: implications for clinical practice. The WOSCOPS Study Group. Eur Heart J 1996; 17(2): 163-4
  12. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90(1): 583-612
  13. Ounpuu S, Negassa A, Yusuf S. INTER-HEART STUDY: A global study of risk factors for acute myocardial infarction. Am Heart J 2001; 141(5): 711-21
  14. Ezzati M. How can cross-country research on health risks strengthen interventions? Lessons from INTERHEART. Lancet 2004; 364(9438): 912-4
  15. Instauration des traitements médicamenteux hypolipémiants en France en 2002, Rev Med Ass Maladie 2003; 34,4 :221-231
  16. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-33
  17. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362(9382): 419-27
  18. Mise au point sur le traitement hormonal substitutif de la ménopause (THS). Afssaps Janvier 2003 [http://www.afssaps.sante.fr]
  19. Mise au point actualisée sur le traitement hormonal substitutif de la ménopause (THS). Afssaps. Décembre 2003 [http://www.afssaps.sante.fr]
  20. Rapport d'orientation sur les traitements hormonaux substitutifs de la ménopause. Anaes/Afssaps. 11 mai 2004 [http://www.afssaps.sante.fr]
  21. Sila CA, Furlan AJ. Therapy for acute ischemic stroke: the door opens. Interpreting the NINDS rt-PA stroke study. Cleve Clin J Med 1996; 63(2): 77-9
  22. Hacke W, Donnan G, Fieschi C, et al. ATLANTIS Trials Investigators. ECASS Trials Investigators. NINDS rt-PA study group investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363(9411): 768-74
  23. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997; 350: 607-14 [CrossRef] [PubMed]
  24. Demchuk AM, Hill MD, Barber PA, et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA stroke study. Stroke 2005; 36(10): 2110-5
  25. The IMPact-RSV study group. Palivizumab, humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102(3): 531-7
  26. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20(17-18): 2166-73
  27. Shapiro ED. Protective efficacy trials. In: Ellis RW. Development and clinical uses of haemophilus b conjugate vaccines. New York, NY: Marcel Dekker; 1994 may; 339-56
  28. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998 Jan;16(1): 301-8
  29. Balant LP, Balant-Gorgia EA. Cultural differences: implications on drug therapy and global drug development. Int J Clin Pharmacol Ther 2000; 38(2): 47-52
  30. American Heart Association, National Heart, Lung and Blood Institute, Grundy SM, et al. Diagnosis and management of metabolic syndrome. Cardiol rev 2005; 13(6): 322-7
  31. Patel A, Huang KC, Janus ED, et al. Is a single definition of the metabolic syndrome appropriate? A comparative study of the USA and Asia. Atherosclerosis 2006; 184(1): 225-32
  32. Veldhuyzen Van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000; 162 (12 suppl): S3-23
  33. Graf J, Doig GS, Cook DJ, et al. Randomized, controlled clinical trials in sepsis: has methodological quality improved over time? Crit Care Med 2002; 30(2): 461-72
  34. Bullinger M, Anderson D, Cella D, et al. Developping and evaluating cross-cultural instruments for minimal requirements to optimal models. Qual Life Res 1993; 2: 451-9